A multipathway phosphopeptide assay development using Stellar Mass Spectrometer with adaptive RT for rapid phosphoproteomic

Importance of the topic

This study addresses targeted phosphoproteomics of human kinase activation loops, a class of regulatory phosphosites that directly control kinase activity and are highly informative readouts of signaling pathway status in cancer. Sensitive and multiplexed quantification of these low-abundance phosphopeptides enables pathway-level biomarker discovery, pharmacodynamic monitoring, and improved molecular phenotyping in oncology research.

Objectives and study overview

The primary aim was to develop a high-plex targeted assay that quantifies hundreds of phosphopeptides from kinase activation loops in a single LC–MS run. The workflow combines a stable-isotope labeled phosphopeptide mixture (>280 heavy-labeled peptides) with an adaptive retention-time (RT) scheduled parallel reaction monitoring (PRM) method on the Thermo Stellar mass spectrometer, and uses MS3 where needed to overcome background interference. The study optimized chromatography, collision energy, AGC and injection timing to maximize sensitivity, specificity, linearity and precision.

Methodology

• Sample preparation: Synthetic heavy-labeled phosphopeptide standards (JPT Peptide Technologies) were spiked into enriched HeLa digests. Phosphopeptide enrichment used the HighSelect Fe-NTA magnetic kit.
• Chromatography: Trap-and-elute Vanquish Neo UHPLC with a 75 µm × 25 cm IonOpticks/Aurora-type column operated at 50 °C; autosampler at 7 °C. Mobile phases: A = 0.1% formic acid in water; B = 0.1% formic acid in 80% acetonitrile. A 45-minute gradient was selected as optimal for balancing throughput and isomer separation.
• Mass spectrometry: Thermo Scientific Stellar mass spectrometer configured for adaptive RT PRM. Key settings included MS2/MS3 scan range ~200–1500 m/z, scan rate 125 kDa/s, RF lens ~30%, isolation window 2 m/z for targeted MS2, HCD activation for MS2 and MS3, and collision energy centered at 23%.
• Acquisition strategy: Adaptive RT scheduling with a 1.8-minute retention-time window for each target peptide, dynamic time scheduling and 7 points per peak. MS3 acquisition was implemented for peptides that showed high background to improve specificity and signal-to-noise.
• Instrument tuning: AGC target evaluated across 100–800% with final method using standard AGC (100%); Dynamic Injection Time mode selected over Auto based on intensity ratios. Data processing performed in Skyline-Daily 26.1.1 with assistance from PRM conductor tools.

Used instrumentation

• Vanquish Neo UHPLC system (trap-and-elute configuration)
• IonOpticks/Aurora-type 75 µm × 25 cm column (EASY-Spray/EASY-SprayTM HPLC ES906A cited)
• Thermo Scientific Stellar mass spectrometer (PRM and MS3 capable)
• HighSelect Fe-NTA Magnetic Phosphopeptide Enrichment Kit (Thermo Scientific)
• Phosphopeptide standards from JPT Peptide Technologies
• Data analysis: Skyline-Daily 26.1.1 and PRM conductor

Main results and discussion

• Multiplex scale and throughput: The adaptive RT PRM method was built to target >280 heavy-labeled phosphopeptides and the 45-minute gradient method encompassed over 570 precursor ions (heavy + light), enabling monitoring of hundreds of kinase activation-loop sites in a single LC–MS run.
• Sensitivity and specificity: Combining adaptive RT scheduling with MS3 for problematic targets improved signal-to-noise and reduced background interference. MS3 acquisitions notably increased detectability for targets in enriched HeLa matrices.
• Chromatography and isomer separation: The 45-minute gradient produced superior separation of positional phosphopeptide isomers compared with shorter gradients (30 min), enabling confident discrimination of phosphorylation sites based on retention time and diagnostic fragment ions.
• Analytical performance: The assay demonstrated strong linearity across multiple on-column concentrations (down to low-fmol/pmol on-column levels) with acceptable precision—reported CVs for representative peptides ranged from low single digits up to ~17% depending on peptide and concentration. Enrichment increased detected phosphopeptide intensities by >100-fold for many targets.
• Stability: Most phosphopeptides remained stable in the autosampler at 7 °C for up to 72 hours, though some peptides showed signal decay at room temperature or after extended storage, highlighting the need to control sample handling for certain markers.
• Operational parameters: Final method choices included CE = 23%, Dynamic Injection Time, standard AGC target (100%), isolation window 2 m/z, and 7 points per peak to preserve quantitation quality.

Benefits and practical applications

• High-throughput pathway readouts: Single-run monitoring of hundreds of kinase activation sites supports pathway profiling in discovery and translational studies.
• Improved confidence in site localization: Chromatographic separation plus targeted MS2/MS3 fragmentation allows resolution of phosphorylation site isomers, critical for interpreting kinase activity and signaling biology.
• Robust quantitative performance: The method delivers observable linearity, accuracy and precision suitable for comparative studies, target validation, and potential biomarker assays.
• Flexible deployment: Adaptive RT scheduling reduces cycle-time burden of large target lists and MS3 can be selectively applied to targets suffering from matrix interference, yielding a practical balance of throughput and specificity.

Future trends and potential applications

• Clinical translation: Extending the panel to clinical sample cohorts (biopsies, plasma-derived EVs) and integrating rigorous QC/standardization could enable pharmacodynamic and diagnostic assays.
• Panel expansion and multiplexing: Increasing phosphosite coverage and combining targeted PRM with complementary DIA/IMS approaches could broaden pathway coverage and resolution of challenging isomers.
• Automation and AI-driven scheduling: Machine-learning optimization of retention-time windows and dynamic scheduling could further increase target capacity and reduce method setup time.
• Improved sample workflows: Integration with higher-recovery enrichment chemistries, microflow LC, or front-end automation will enhance sensitivity and throughput for large cohorts.
• Orthogonal structural resolution: Coupling ion mobility or alternative fragmentation strategies may further disambiguate positional isomers and complex PTM patterns.

Conclusion

The reported adaptive RT PRM workflow on the Stellar mass spectrometer provides a scalable, sensitive and specific solution for targeted phosphoproteomics of kinase activation loops. By combining a 45-minute chromatographic method, adaptive scheduling, optimized instrument settings, and selective MS3 for noisy targets, the approach enables high-plex quantification, confident site localization, and robust analytical metrics suitable for pathway-focused cancer research and biomarker development.

Reference

• 1. Cancer Letters. 2013 Sep 2;342(1):104–112.
• 2. Clinical Cancer Research. 2010 Nov 1;16(21):5124–5132.